ASP Isotopes Inc. Signs $4 Million Supply Deal with Isotopia for Gadolinium-160 to Boost Cancer Therapy Production

Reuters

06/04

<a href="https://laohu8.com/S/ASPI">ASP Isotopes Inc.</a> Signs $4 Million Supply Deal with Isotopia for Gadolinium-160 to Boost Cancer Therapy Production

ASP Isotopes Inc. has announced a significant supply agreement with Isotopia Molecular Imaging Ltd. to provide enriched Gadolinium-160 (Gd-160), a crucial precursor for producing Terbium-161 (Tb-161). The four-year contract, starting in 2026, is valued at a minimum of $1 million annually. This partnership aims to address longstanding supply challenges for Gd-160, facilitating the advancement of Tb-161-based therapies for cancers such as prostate cancer and neuroendocrine tumors. ASP Isotopes will utilize its Quantum Enrichment technology to ensure a stable supply of Gd-160, supporting Isotopia's efforts to scale production and advance Tb-161-labeled drug candidates toward commercialization. This collaboration is expected to accelerate the clinical adoption of Tb-161, potentially redefining cancer treatment paradigms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ASP Isotopes Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9463133-en) on June 04, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540065487"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540065487\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540065487?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-04 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540065487","market":"us","top_or_hot":-1,"title":"ASP Isotopes Inc. Signs $4 Million Supply Deal with Isotopia for Gadolinium-160 to Boost Cancer Therapy Production","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ASPI\">ASP Isotopes Inc.</a> Signs $4 Million Supply Deal with Isotopia for Gadolinium-160 to Boost Cancer Therapy Production\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ASP Isotopes Inc. has announced a significant supply agreement with Isotopia Molecular Imaging Ltd. to provide enriched Gadolinium-160 (Gd-160), a crucial precursor for producing Terbium-161 (Tb-161). The four-year contract, starting in 2026, is valued at a minimum of $1 million annually. This partnership aims to address longstanding supply challenges for Gd-160, facilitating the advancement of Tb-161-based therapies for cancers such as prostate cancer and neuroendocrine tumors. ASP Isotopes will utilize its Quantum Enrichment technology to ensure a stable supply of Gd-160, supporting Isotopia's efforts to scale production and advance Tb-161-labeled drug candidates toward commercialization. This collaboration is expected to accelerate the clinical adoption of Tb-161, potentially redefining cancer treatment paradigms.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ASP Isotopes Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9463133-en) on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASP Isotopes Inc. Signs $4 Million Supply Deal with Isotopia for Gadolinium-160 to Boost Cancer Therapy Production</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASP Isotopes Inc. Signs $4 Million Supply Deal with Isotopia for Gadolinium-160 to Boost Cancer Therapy Production\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-04 20:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ASPI\">ASP Isotopes Inc.</a> Signs $4 Million Supply Deal with Isotopia for Gadolinium-160 to Boost Cancer Therapy Production\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ASP Isotopes Inc. has announced a significant supply agreement with Isotopia Molecular Imaging Ltd. to provide enriched Gadolinium-160 (Gd-160), a crucial precursor for producing Terbium-161 (Tb-161). The four-year contract, starting in 2026, is valued at a minimum of $1 million annually. This partnership aims to address longstanding supply challenges for Gd-160, facilitating the advancement of Tb-161-based therapies for cancers such as prostate cancer and neuroendocrine tumors. ASP Isotopes will utilize its Quantum Enrichment technology to ensure a stable supply of Gd-160, supporting Isotopia's efforts to scale production and advance Tb-161-labeled drug candidates toward commercialization. This collaboration is expected to accelerate the clinical adoption of Tb-161, potentially redefining cancer treatment paradigms.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ASP Isotopes Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9463133-en) on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"納斯達克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL6ZKbwT:1","article_id":"2540065487","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540065487","pubTimestamp":1749040234,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ASP Isotopes Inc. has announced a significant supply agreement with Isotopia Molecular Imaging Ltd. to provide enriched Gadolinium-160 , a crucial precursor for producing Terbium-161 . The four-year contract, starting in 2026, is valued at a minimum of $1 million annually. This partnership aims to address longstanding supply challenges for Gd-160, facilitating the advancement of Tb-161-based therapies for cancers such as prostate cancer and neuroendocrine tumors. ASP Isotopes will utilize its Quantum Enrichment technology to ensure a stable supply of Gd-160, supporting Isotopia's efforts to scale production and advance Tb-161-labeled drug candidates toward commercialization. This collaboration is expected to accelerate the clinical adoption of Tb-161, potentially redefining cancer treatment paradigms.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","ASPI":"ASP Isotopes Inc.","BK4109":"特种化学制品","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股"},"translate_title":"ASP Isotopes Inc.与Isotopia签署价值400万美元的钆160供应协议，以提高癌症治疗产量","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ASPI":0.9},"content_text":"ASP Isotopes Inc. Signs $4 Million Supply Deal with Isotopia for Gadolinium-160 to Boost Cancer Therapy Production\n    \n\n        ASP Isotopes Inc. has announced a significant supply agreement with Isotopia Molecular Imaging Ltd. to provide enriched Gadolinium-160 (Gd-160), a crucial precursor for producing Terbium-161 (Tb-161). The four-year contract, starting in 2026, is valued at a minimum of $1 million annually. This partnership aims to address longstanding supply challenges for Gd-160, facilitating the advancement of Tb-161-based therapies for cancers such as prostate cancer and neuroendocrine tumors. ASP Isotopes will utilize its Quantum Enrichment technology to ensure a stable supply of Gd-160, supporting Isotopia's efforts to scale production and advance Tb-161-labeled drug candidates toward commercialization. This collaboration is expected to accelerate the clinical adoption of Tb-161, potentially redefining cancer treatment paradigms.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ASP Isotopes Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9463133-en) on June 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}